Ancion, M. (2024). Approach using "second-generation" immune checkpoint inhibitors for the treatment of triple-negative breast cancer [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/316529 |
Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (06 February 2024). Exploring the impact of methylglyoxal stress on tumor immunity [Poster presentation]. Séminaire Télévie 2024. |
Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., Janji, B., & Bellahcene, A. (27 October 2023). Methylglyoxal stress : a novel role in tumor immunity ? [Poster presentation]. Annual Meeting of the Belgian Association for Cancer Research (BACR). |
Ancion, M., Luyckx, M., Renard, M., Reynders, C., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., RONCARATI, P., Herfs, M., & Hubert, P. (12 June 2023). Approach using "second generation" immune checkpoint inhibitors for the treatment of triple-negative breast cancer [Poster presentation]. EACR 2023, Turin, Italy. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Luyckx, M., Renard, M., Delvenne, P., Hubert, P., & Herfs, M. (02 February 2023). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV in carcinogenesis [Poster presentation]. Séminaire des chercheurs Télévie 2023. |
Ancion, M. (02 February 2023). Approach using "second generation" immune checkpoints for the treatment of triple-negative breast cancer [Poster presentation]. Télévie Seminar 2023, Woluwe, Belgium. |
Ancion, M. (02 February 2023). Approach using "second generation" immune checkpoint inhibitors for the treatment of triple-negative breast cancer [Paper presentation]. Séminaire des chercheurs Télévie 2023, Woluwe, Belgium. |
Bruyere, D., RONCARATI, P., Lebeau, A., Lerho, T., Poulain, F., Hendrick, E., Pilard, C., Reynders, C., Ancion, M., Luyckx, M., Renard, M., Jacob, Y., Twizere, J.-C., Peiffer, R., Peulen, O., Delvenne, P., Hubert, P., McBride, A., Gillet, N., ... Herfs, M. (2023). Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair. Theranostics, 13 (3), 1130 - 1149. doi:10.7150/thno.78091 Peer Reviewed verified by ORBi |
Mohring, V., Hubert, P., Ancion, M., Nokin, M.-J., Roncarati, P., Agirman, F., Maloujahmoum, N., Lardinois, F., Wissocq, T., Herfs, M., Peulen, O., & Janji, B. (2023). Enhancement of anti-tumor immunity through interference with glycation stress in breast cancer [Poster presentation]. GIGA day. |
Reynders, C., Roncarati, P., Ancion, M., Lerho, T., Bruyère, D., Delvenne, P., Hubert, P., & Herfs, M. (29 September 2022). Caractérisations histopathologiques des cancers œsophagiennes et potentiel implication des infections par HPV de haut-risques [Paper presentation]. Conférence annuelle de l'Association Francophone pour l'étude des Infections à Papillomavirus et Polyomavirus 2022, France. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Bruyère, D., Hendrick, E., Delvenne, P., Hubert, P., & Herfs, M. (09 September 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV in carcinogenesis [Poster presentation]. INTERUNIVERSITY PHD STUDENT DAY. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Hendrick, E., Bruyère, D., Delvenne, P., Hubert, P., & Herfs, M. (06 September 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV infections in carcinogenesis [Poster presentation]. GIGA-Day 2022. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., Delvenne, P., Hubert, P., & Herfs, M. (29 April 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV in carcinogenesis [Paper presentation]. Séminaire du GIGA-Cancer, Belgium. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Hendrick, E., Bruyère, D., Pilard, C., Delvenne, P., Hubert, P., & Herfs, M. (08 April 2022). Histopathological characterization of esophageal cancers and potential role of high-risk HPV infections [Poster presentation]. Séminaire des chercheurs Télévie 2022, Belgium. |
Lebeau, A.* , Bruyère, D.* , RONCARATI, P., Peixoto, P., Hervouet, E., COBRAIVILLE, G., Taminiau, B., Masson, M., Gallego, C., Mazzucchelli, G., Smargiasso, N., Fleron, M., Baiwir, D., Hendrick, E., Pilard, C., Lerho, T., Reynders, C., Ancion, M., GREIMERS, R., ... Herfs, M. (28 February 2022). HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nature Communications, 13 (1), 1076. doi:10.1038/s41467-022-28724-8 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Bruyère, D., Hendrick, E., Delvenne, P., Hubert, P., & Herfs, M. (14 December 2021). Histopathological characterization of esophageal cancers and potential role of high-risk HPV infections [Poster presentation]. Giga Cancer Day 2021. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., Hubert, P., Delvenne, P., & Herfs, M. (01 October 2021). Caractérisation histopathologique des cancers œsophagiens et potentiel rôle des HPV [Paper presentation]. Conférence annuelle de l'Association Francophone pour l'étude des Infections à Papillomavirus et Polyomavirus, France. |
Ancion, M. (09 June 2021). Theurapeutic approach combining PD-1/PD-L1 blockade and the inhibition of "new" immune checkpoints for the treatment of triple-negative breast cancer [Poster presentation]. European Association for Cancer Research Congress 2021. |
Baudu, T., Parratte, Perez, V., Ancion, M., Millevoi, S., Hervouet, E., Peigney, A., Peixoto, P., Overs, A., Herfs, M., Fraichard, A., Guittaut, M., & Baguet, A. (2021). The NMD Pathway Regulates GABARAPL1 mRNA during the EMT. Biomedicines. doi:10.3390/biomedicines9101302 Peer Reviewed verified by ORBi |
Bruyère, D., Monnien, F., Colpart, P., RONCARATI, P., Vuitton, L., Hendrick, E., Lepinoy, A., Luquain, A., Pilard, C., Lerho, T., Molimard, C., Maingon, P., Arnould, L., Bone-Lepinoy, M.-C., Dusserre, L., Martin, L., Reynders, C., Ancion, M., Peiffert, D., ... Herfs, M. (2021). Treatment algorithm and prognostic factors for patients with stage I–III carcinoma of the anal canal: a 20-year multicenter study. Modern Pathology, 34, 116-130. doi:10.1038/s41379-020-0637-6 Peer Reviewed verified by ORBi |
Pilard, C.* , Ancion, M.* , Delvenne, P., JERUSALEM, G., Hubert, P., & Herfs, M. (2021). Cancer immunotherapy: it’s time to better predict patients’ response. British Journal of Cancer, 125(7), 927-938. doi:10.1038/s41416-021-01413-x Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Jacquet, M., Hervouet, E., Baudu, T., Herfs, M., Parratte, C., Feugeas, J.-P., Perez, V., Reynders, C., Ancion, M., Vigneron, M., Baguet, A., Guittaut, M., Fraichard, A., & Despouy, G. (2021). GABARAPL1 Inhibits EMT Signaling through SMAD-Tageted Negative Feedback. Biology. doi:10.3390/biology10100956 Peer reviewed |
Hubert, P., RONCARATI, P., Demoulin, S., Pilard, C., Ancion, M., Reynders, C., Lerho, T., Bruyère, D., Lebeau, A., Radermecker, C., Meunier, M., Nokin, M.-J., Hendrick, E., Peulen, O., Delvenne, P., & Herfs, M. (2021). Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Journal for ImmunoTherapy of Cancer, 9 ((3)), 001966. doi:10.1136/jitc-2020-001966 Peer Reviewed verified by ORBi |
Pilard, C., RONCARATI, P., Hendrick, E., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (03 November 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Paper presentation]. Cytokines 2020, Seattle (Virtual), United States. |
Pilard, C., RONCARATI, P., Hendrick, E., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (03 October 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. 7th Immunotherapy of Cancer Conference (ITOC7), Munich (Virtual), Germany. |
Pilard, C., RONCARATI, P., Hendrick, E., Lebeau, A., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (01 October 2020). P08.03 Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy. Journal for ImmunoTherapy of Cancer, 8 (Suppl 2), 50-A51. doi:10.1136/jitc-2020-ITOC7.99 |
Pilard, C., RONCARATI, P., Hendrick, E., Lebeau, A., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (07 February 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. BACR 2020, Jette, Belgium. |
Pilard, C., RONCARATI, P., Hendrick, E., Lebeau, A., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (29 January 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. Télévie Seminar 2020, Bruxelles, Belgium. |
Terren, C., Fransolet, M., Ancion, M., Nisolle, M., & Munaut, C. (23 December 2019). Slow Freezing Versus Vitrification of Mouse Ovaries: from Ex Vivo Analyses to Successful Pregnancies after Auto-Transplantation. Scientific Reports, 9 (1), 19668. doi:10.1038/s41598-019-56182-8 Peer Reviewed verified by ORBi |